Clinical Trials Logo
  1. Home
  2. Type I Hypersensitivity
  3. NCT00258635

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

Type I Hypersensitivity Clinical Trial

Official title:
A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Ragweed Allergoid With MPL® With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Patients Sensitized to Ragweed Pollen.

Clinical Trial Summary

The purpose of this study is to assess the immunological differences between three RagweedMATAMPL treatment arms compared to placebo with respect to immunoglobulin levels. In addition, the study will assess the reduced allergenicity of modified Ragweed Pollen contained in RagweedMATAMPL compared to unmodified native allergen using skin prick testing.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00258635
Study type Interventional
Source Allergy Therapeutics
Contact
Status Completed
Phase Phase 2
Start date November 2005
Completion date August 7, 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT00133146 - Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine Phase 2
Completed NCT00133159 - Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen Phase 2
Terminated NCT00387478 - Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis Phase 2
Completed NCT00414141 - Efficacy and Safety/Tolerability of Grass MATA MPL Phase 3
Completed NCT00325338 - Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis Phase 2
Completed NCT00110786 - Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy Phase 2
Withdrawn NCT00109759 - Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A) Phase 1
Completed NCT00423787 - Efficacy and Safety/Tolerability of Ragweed MATA MPL Phase 3
Completed NCT00104377 - Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen Phase 2
Completed NCT00104390 - Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing Phase 1
Completed NCT00116285 - Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing Phase 1
Completed NCT00118612 - Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen Phase 2
Completed NCT00118625 - Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine Phase 2
Completed NCT00113750 - Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen Phase 2
Completed NCT00241410 - Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen Phase 1
Completed NCT00107705 - Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing Phase 1